Kerecis is the fastest-growing and one of the top five companies in the U.S. biologics-skin and dermal-substitute market, according to SmartTRAK Business Intelligence
Shield Standard combines a fish-skin graft and silicone backing for efficient treatment of acute and chronic wounds. (Credit: Business Wire)
Kerecis, the company pioneering the use of sustainably sourced fish skin and fatty acids in cellular therapy and tissue regeneration and protection, today announced the availability of Shield Standard, which combines a fish-skin graft and silicone backing for efficient treatment of acute and chronic wounds.
Shield Standard is a part of the Kerecis Shield product family, which is designed for managing chronic and acute wounds such as diabetic foot ulcers, pressure ulcers, vascular ulcers, post-Moh’s surgical wounds, and draining wounds. The grafts contain essential natural skin elements and are fenestrated to allow adequate wound drainage for appropriate wound moisture at the wound bed.
“The positive feedback we have received from healthcare professionals for the silicone fish-skin combination products has encouraged us to expand the product range,“ said Fertram Sigurjonsson, Founder and CEO of Kerecis. “We’ve seen remarkable outcomes from the initial silicone combination product, Shield Adhesive, and are committed to filling the demand for greater variety in wound solutions.”
Source: Company Press Release